Clinical Trial Adverse Event Reporting To Be Discussed At FDA Public Hearing
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency announces March 21 hearing to consider the types of adverse event reports that should be submitted to institutional review boards. The proliferation of multi-center studies is one reason behind FDA’s decision to revisit the process by which IRBs assess such information.